Guava Technologies announced unexpectedly last week that Rajen Dalal, the company’s president and CEO for the last three years, has resigned.

Taking over for Dalal on an interim basis is John Walker, the chairman of Guava’s board of directors.

Last week, Dalal told Inside Bioassays that his decision to resign was primarily due to a disagreement about which markets Guava should commit the bulk of its money to over the coming year: drug-discovery tools or clinical diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.